14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium
1 Infection related and unrelated malignancies, HIV and the aging population. L Shepherd on behalf of EuroSIDA in EuroCoord. presentation
2 The spectrum of clinical disease and relationship with measures of deteriorating renal function. A Mocroft on behalf of EuroSIDA in EuroCoord. presentation
3 Management of cardiovascular risk in HIV positive individuals in Europe. M Shahmanesh on behalf of EuroSIDA in EuroCoord presentation
4 Prevalence of detected drug resistance across different regions of Europe: Data from EuroSIDA 1997-2012. A Schultze on behalf of EuroSIDA in EuroCoord. presentation
5 Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers in HIV-infected persons. JP Viard on behalf of EuroSIDA in EuroCoord. presentation
6 Organisation and delivery of healthcare for HIV/TB coinfected patients in Europe. M Mansfeld on behalf of the TB:HIV study in EuroCoord. presentation
7 Response to combination antiretroviral treatment in HIV-positive individuals in Europe: variation by educational level. J del Amo for the socio-economic inequalities working group of COHERE in EuroCoord. presentation
8 Mortality in migrants living with HIV in Western European countries: differences by geographical origin and gender. S Monge on behalf of the migrants working group of COHERE in EuroCoord. presentation
9 Obese HIV-infected patients treated with efavirenz-containing regimens are at risk of virological failure. C Marzolini on behalf of the obesity working group of COHERE in EuroCoord. presentation
10 Prediction of global CVD risk in HIV-positive persons. N Friis Møller, L Ryom, C Smith, R Weber, P Reiss, F Dabis, S De Wit, A D´Arminio Monforte, O Kirk, E Fontas, C Sabin, A Phillips, J Lundgren, M Law for the D:A:D Study group. presentation
1 Investigating the causal impact of PI- and NNRTI-containing cART on the risk of mortality: methodological challenges. C Smith et al. for the D:A:D Study Group. poster
2 Development of thrombocytopenia and risk of AIDS and serious non-AIDS events in Europe. AH Borges et al. on behalf of EuroSIDA in EuroCoord. poster
3 Estimation of percentage of HIV-infected people with limited future drug options in a closed observational setting over the period 2007-2011 and beyond. A Cozzi-Lepri et al. for EuroSIDA in EuroCoord. poster
4 Is Stavudine (D4T) still being used in EuroSIDA despite its association with toxicity and a higher frequency of sever adverse events. D Grint et al. for EuroSIDA in EuroCoord. poster
5 Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons: results from the EuroSIDA cohort study. J-P Viard, et al. on behalf of EuroSIDA in EuroCoord. poster
6 Management of cardiovascular risk in HIV positive individuals in Europe. M Shahmanesh, et al. on behalf of EuroSIDA in EuroCoord. poster
7 A survey of ATRIPLA use in clinical practice among treatment-naïve HIV-positive patients in Europe. O Kirk et al. for EuroSIDA in EuroCoord. poster
8th European Congress on Tropical Medicine and International Health. Copenhagen, 10-13 September 2013
1 Health service delivery models for the provision of antiretroviral therapy in sub-Saharan Africa: A systematic review. Jeff Lazarus.
2 The Global WHO/Hepatitis Alliance Survey and Hepatitis and drug use in Europe - a systematic review. Jeff Lazarus
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June - 3 July, Kuala Lumpur
Late HIV diagnosis, late initiation of combination ART and mortality in Europe: variation by educations level. Sara Lodi on behalf of COHERE in EuroCoord.
Prevalence and impact of transmitted drug resistance (TDR) on response to ART in children. Nicole Ngo-Giang-Huong and Linda Wittkop on behalf of EuroCoord-CHAIN-EPPICC project team.
13th International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, 4-8 June 2013, Toronto, Canada
Low-frequency drug-resistant HIV-1 and risk of virological failure to firts-line NNRTI-based ART: a multi-cohort European case-control study using centralized ultrasensitive 454 sequencing. A Cozzi-Lepri, M Noguera-Julian, F Di Giallonardo, R Schuurman, M Däumer, S Aitken, HF Günthard, F Brun-Vezinet, KJ Metzner, R Paredes, and the CHAIN Minority HIV-1 Variants Working Group.
20th International HIV Dynamics and Evolution Conference, 8-11 May 2013, Utrecht, The Netherlands
The Colombian epidemic is dominated by HIV-1 subtype B: A molecular epidemiology and phylodynamic study. AC Pineda, NR Faria, FJ Diaz, P Olaya, CM Frederiksen, L Guangdi, A Gomez-Lopez, P Lemey, AM Vandamme. poster
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta
1 Increased risk of cardiovascular disease (CVD) with age in men: a comparison of D:A:D with HIV negative CVD risk equations. K Petoumenos, W El-Sadr, A d’Arminio Monforte, C Sabin, P Reiss, L Ryom, S De Wit, M Rickenbach, JD Lundgren and MG Law for the D:A:D Study group.
1 Cancer Risk and Use of PI or NNRTI-based Combination Antiretroviral Therapy (cART): The D:A:D Study. M Bruyand, L Ryom, L Shepherd, P Reiss, S de Wit, A d’Arminio Monforte, M Rickenbach, A Philips, C Pradier, M Law, W El-Sadr, J Lundgren, C Sabin for the D:A:D study group.
2 Predictors of Advanced Chronic Kidney Disease and End-Stage Renal Disease in HIV-Positive Persons in D:A:D. L Ryom, A Mocroft, O Kirk, M Ross, P Reiss, W El-Sadr, S de Wit, P Morlat, O Moranne, CA Fux, A d’Arminio Monforte, M Law and JD Lundgren for the D:A:D Study group.
3 Improvements in short-term mortality following myocardial infarction (MI): the D:A:D Study.C Sabin, L Ryom, M Law, W El-Sadr, O Kirk, M Bruyand, P Reiss, C Pradier, B Ledergerber, A d’Arminio Monforte, S de Wit, JD Lundgren on behalf of the D:A:D Study Group.
4 The incidence of AIDS defining events (ADEs) at a current CD4 count ≥ 200/mm3 in the post combination antiretroviral therapy era. Amanda Mocroft on behalf of the Opportunistic Infections Working Group of COHERE in EuroCoord.